학술논문

Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study
Document Type
article
Source
Journal of Personalized Medicine. 13(5)
Subject
Rare Diseases
Cancer
Liver Disease
Orphan Drug
Pancreatic Cancer
Digestive Diseases
Development of treatments and therapeutic interventions
2.1 Biological and endogenous factors
5.1 Pharmaceuticals
Aetiology
Good Health and Well Being
pancreatic cancer
liver metastasis
selective targeting
fluorescent antibody
imaging
mucin
Language
Abstract
Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugated to an IR800 dye (MUC5AC-IR800) to preferentially label a liver metastasis of pancreatic cancer (Panc Met) in a unique patient-derived orthotopic xenograft (PDOX) model. In orthotopic models, the mean tumor to background ratio was 1.787 (SD ± 0.336), and immunohistochemistry confirmed the expression of MUC5AC within tumor cells. MUC5AC-IR800 provides distinct visualization of pancreatic cancer liver metastasis in a PDOX mouse model, demonstrating its potential utility in staging laparoscopy and fluorescence-guided surgery.